Kulcsár-Gergely J, Kulcsár A
Department of Pharmacology, Medical University, Debrecen, Hungary.
Arzneimittelforschung. 1992 Oct;42(10):1192-5.
The effects of beta 1-selective metoprolol (CAS 37350-58-6) and the nonselective beta-adrenoceptor antagonist propranolol (CAS 525-66-6) were investigated in healthy and CCl4 damaged male rats. Treatments were performed for 16 days, orally with dosages reducing heart beat/min by 25% (metoprolol 10 mg/kg, propranolol 1 mg/kg). Liver glycogen content was not influenced by either beta-blocker in healthy animals. CCl4-induced loss of glycogen was equally moderated by metoprolol and propranolol. Blood glucose increased in metoprolol treated healthy and liver damaged rats after a single dosage likewise following prolonged treatment. Propranolol was without effect on blood glucose level. Cytochrome P-450 decline in microsomal fraction was greater in metoprolol, than in propranolol treated healthy animals. However, the severe fall elicited by liver injury was moderated by metoprolol and normalised by propranolol. Cytochrome b5 seems to be involved in metoprolol metabolism. Cytochrome P-450-dependent aminopyrine-N-demethylase was impeded by metoprolol in animals with healthy liver. The serious inhibition caused by CCl4 was moderated by metoprolol and with a better result by propranolol. The high serum bilirubin level in liver lesion was lowered by metoprolol and particularly by propranolol. Neither phase I metabolic process aminopyrine-N-demethylation nor phase II glucuronidation were normalised. A comparison of this data with the results of a previous 12-day treatment schedule indicates that no changes in efficacy occurred with longer treatment. The present results pertain to the importance of the selection of beta-adrenoceptor blocker in liver lesion.(ABSTRACT TRUNCATED AT 250 WORDS)
在健康和四氯化碳损伤的雄性大鼠中研究了β1选择性美托洛尔(CAS 37350-58-6)和非选择性β肾上腺素能受体拮抗剂普萘洛尔(CAS 525-66-6)的作用。治疗持续16天,口服给药,剂量以将心率/分钟降低25%为准(美托洛尔10毫克/千克,普萘洛尔1毫克/千克)。在健康动物中,两种β受体阻滞剂均未影响肝糖原含量。美托洛尔和普萘洛尔对四氯化碳诱导的糖原损失的缓解程度相同。单次给药后,美托洛尔治疗的健康和肝损伤大鼠的血糖升高,长期治疗后同样如此。普萘洛尔对血糖水平无影响。在美托洛尔治疗的健康动物中,微粒体部分细胞色素P-450的下降幅度大于普萘洛尔治疗的动物。然而,肝损伤引起的严重下降被美托洛尔缓解,被普萘洛尔恢复正常。细胞色素b5似乎参与美托洛尔的代谢。在肝脏健康的动物中,美托洛尔会阻碍细胞色素P-450依赖的氨基比林-N-脱甲基酶。四氯化碳引起的严重抑制被美托洛尔缓解,普萘洛尔的效果更好。肝损伤时的高血清胆红素水平被美托洛尔降低,特别是被普萘洛尔降低。I相代谢过程氨基比林-N-脱甲基化和II相葡萄糖醛酸化均未恢复正常。将这些数据与之前12天治疗方案的结果进行比较表明,延长治疗时间疗效无变化。目前的结果涉及在肝损伤中选择β肾上腺素能受体阻滞剂的重要性。(摘要截短于250字)